🇺🇸 FDA
Patent

US 11197844

Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

granted A61KA61K31/155A61K31/337

Quick answer

US patent 11197844 (Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer) held by The Regents of the University of California expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/155, A61K31/337, A61K31/351, A61K31/366